Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with ...

In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a ...

Texas McCombs Expands MD-MBA Pipeline To Houston With New Dual Degree

Texas McCombs’ new Houston campus in the CityCentre district will host its Working Professional MBA program, where M.D./MBA ...
Wealth Management

Why Emerging Markets Equities Still Look Like a Smart Play

Despite the war in Iran, emerging markets still look poised for growth, says Derrick Irwin, a senior portfolio manager at ...

Boehringer Ingelheim Limited: Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic ...

In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight l ...
Bank of Canada

Annual Report 2025

Release of the Monetary Policy Report – Press conference by Governor Tiff Macklem and Senior Deputy Governor Carolyn Rogers ...